Great West Life Assurance CO Alnylam Pharmaceuticals, Inc. Transaction History

Great West Life Assurance CO

$49.6 Billion
Q1 2024

A detailed history of Great West Life Assurance CO transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 47,545 shares of ALNY stock, worth $11.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

47,545

Previous 45,741 3.94%

Holding current value

$11.3 Million

Previous $8.7 Million 18.34%

% of portfolio

0.01%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$146.51 - $198.2 $264,304 - $357,552	1,804 Added 3.94%	47,545 $7.11 Million
Q4 2023 Feb 13, 2024	BUY	$151.41 - $196.57 $237,410 - $308,221	1,568 Added 3.55%	45,741 $8.7 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $130,468 - $161,700	-764 Reduced 1.7%	44,173 $7.82 Million
Q2 2023 Aug 10, 2023	BUY	$185.01 - $212.05 $356,699 - $408,832	1,928 Added 4.48%	44,937 $8.59 Million
Q1 2023 May 12, 2023	BUY	$182.66 - $235.53 $127,862 - $164,871	700 Added 1.65%	43,009 $8.63 Million

Q4 2022 Feb 10, 2023	SELL	$185.53 - $241.31 $57,143 - $74,323	-308 Reduced 0.72%	42,309 $10.1 Million
Q3 2022 Nov 01, 2022	BUY	$138.54 - $232.0 $5.9 Million - $9.89 Million	42,617 New	42,617 $8.51 Million
Q2 2022 Aug 09, 2022	SELL	$120.42 - $169.29 $1.49 Million - $2.1 Million	-12,385 Reduced 19.86%	49,984 $7.3 Million
Q1 2022 May 12, 2022	BUY	$127.18 - $173.91 $1.39 Million - $1.89 Million	10,892 Added 21.16%	62,369 $10.8 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $2.51 Million - $3.29 Million	-15,739 Reduced 23.42%	51,477 $8.71 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $619,927 - $758,629	-3,652 Reduced 5.15%	67,216 $12.8 Million
Q2 2021 Aug 11, 2021	SELL	$128.63 - $176.89 $1.12 Million - $1.54 Million	-8,697 Reduced 10.93%	70,868 $12 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $893,517 - $1.24 Million	7,045 Added 9.71%	79,565 $11.2 Million
Q4 2020 Feb 16, 2021	BUY	$122.97 - $147.0 $1.44 Million - $1.72 Million	11,676 Added 19.19%	72,520 $9.41 Million
Q3 2020 Nov 17, 2020	SELL	$121.19 - $165.49 $46.1 Million - $63 Million	-380,717 Reduced 86.22%	60,844 $8.86 Million
Q3 2020 Nov 13, 2020	BUY	$121.19 - $165.49 $46.1 Million - $62.9 Million	380,090 Added 618.32%	441,561 $64.3 Million
Q2 2020 Aug 17, 2020	BUY	$104.21 - $156.44 $1.6 Million - $2.41 Million	15,382 Added 33.37%	61,471 $9.06 Million
Q1 2020 May 14, 2020	BUY	$93.12 - $133.99 $8,194 - $11,791	88 Added 0.19%	46,089 $5.05 Million
Q4 2019 Feb 11, 2020	BUY	$74.51 - $124.23 $3.43 Million - $5.71 Million	46,001 New	46,001 $5.3 Million
Q3 2019 Oct 25, 2019	SELL	$70.9 - $87.82 $2.99 Million - $3.7 Million	-42,171 Closed	0 $0
Q2 2019 Jul 31, 2019	SELL	$65.86 - $92.79 $674,472 - $950,262	-10,241 Reduced 19.54%	42,171 $0
Q1 2019 May 08, 2019	BUY	$72.76 - $93.45 $966,762 - $1.24 Million	13,287 Added 33.96%	52,412 $4.89 Million
Q4 2018 Feb 12, 2019	SELL	$62.67 - $88.33 $9,713 - $13,691	-155 Reduced 0.39%	39,125 $2.73 Million
Q3 2018 Nov 13, 2018	SELL	$87.52 - $122.67 $781,203 - $1.09 Million	-8,926 Reduced 18.52%	39,280 $3.44 Million
Q2 2018 Aug 10, 2018	BUY	$88.31 - $107.8 $148,802 - $181,643	1,685 Added 3.62%	48,206 $4.75 Million
Q1 2018 May 10, 2018	BUY	$115.92 - $148.54 $1.87 Million - $2.4 Million	16,159 Added 53.22%	46,521 $5.55 Million
Q4 2017 Feb 09, 2018	BUY	$114.49 - $139.98 $2.46 Million - $3 Million	21,458 Added 240.99%	30,362 $3.85 Million
Q3 2017 Nov 09, 2017	BUY	$72.53 - $118.27 $645,807 - $1.05 Million	8,904	8,904 $1.05 Million

Others Institutions Holding ALNY

# of Institutions

591

Shares Held

104M

Call Options Held

2.82M

Put Options Held

1.75M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.

Account

Great West Life Assurance CO Alnylam Pharmaceuticals, Inc. Transaction History